SITC 2019 preview – Pieris joins the quest for a better Herceptin
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Upcoming events – key tests approach for Kadmon and Surface
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
Triple meeting – targeted focus validates Merus’s change of tack
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Astra guns for quick cancer and lupus filings
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
Shock revelation sees Biogen erase its aducanumab losses
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
Upcoming events – Roche braves liver cancer and Incyte looks for a new Jak
In liver cancer Roche hopes to succeed where Bristol failed, while Incyte tests its Jakafi follow-on in first-line graft-versus-host disease.
Alder won’t solve Lundbeck’s headaches
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus
Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.